Newer markers for hepatocellular carcinoma

Area of Science:

• Hepatology and Oncology
• Biomarker Discovery
• Cancer Surveillance

Background:

• Hepatocellular carcinoma (HCC) incidence is rising globally, with poor survival rates due to late diagnosis.
• Cirrhosis is the primary risk factor for HCC development.
• Current surveillance using alpha-fetoprotein (AFP) and ultrasonography has limitations in sensitivity and practicality.

Purpose of the Study:

• To highlight the urgent need for novel, sensitive, and specific biomarkers for early HCC detection.
• To discuss the limitations of existing biomarkers and surveillance strategies.
• To emphasize the importance of a structured validation framework for new biomarkers.

Main Methods:

• Review of current literature on HCC biomarkers and surveillance methods.
• Analysis of limitations in existing studies, including sample size and assay heterogeneity.
• Examination of the National Cancer Institute's proposed biomarker validation phases.

Main Results:

• Existing biomarkers like des-gamma carboxyprothrombin and IGF-1 show promise but lack clinical validation.
• Current literature suffers from small sample sizes, inconsistent methodologies, and limited longitudinal data.
• A significant gap exists in validated, non-invasive biomarkers for early HCC detection.

Conclusions:

• Novel biomarkers are urgently required for effective early detection of hepatocellular carcinoma.
• A standardized, rigorous validation process is essential for clinical implementation of new HCC biomarkers.
• The National Cancer Institute's framework offers a roadmap for future biomarker validation studies.